Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chronic Obstructive Pulmonary Disease-II: Pathophysiology01:20

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

2.8K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
2.8K
Chronic Obstructive Pulmonary Disease-I: Introduction01:20

Chronic Obstructive Pulmonary Disease-I: Introduction

2.8K
Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.
2.8K
Chronic Obstructive Pulmonary Disease01:22

Chronic Obstructive Pulmonary Disease

1.2K
COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
1.2K
Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.01:25

Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.

2.8K
Understanding the variety of primary symptoms and systemic complications that characterize chronic obstructive pulmonary disease (COPD) is crucial for healthcare professionals.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
2.8K
COPD: Pathogenesis and Clinical Features01:20

COPD: Pathogenesis and Clinical Features

274
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
274
Cystic Fibrosis: Pathogenesis01:23

Cystic Fibrosis: Pathogenesis

244
Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
244

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comparative Effectiveness and Safety of Fluticasone-Umeclidinium-Vilanterol and Beclomethasone-Glycopyrronium-Formoterol Single-Inhaler Triple Therapies for COPD: Real-World Observational Study [Letter].

International journal of chronic obstructive pulmonary disease·2026
Same author

COPD Biologics: Right Patient, Right Pathway, Right Time.

Pulmonary therapy·2026
Same author

Mucus Plug Formation is Associated with Eosinophilic Activation in Chronic Obstructive Pulmonary Disease.

American journal of respiratory and critical care medicine·2026
Same author

Airway Mucus Plugs in Asthma and COPD: Pathobiology, Imaging, and Implications for Clinical Trials.

American journal of respiratory and critical care medicine·2026
Same author

Every Exacerbation Counts: Shifting the Dial for Future Exacerbation Risk.

American journal of respiratory and critical care medicine·2026
Same author

Small airways obstruction predicts cardiovascular disease incidence: a longitudinal study of UK Biobank.

ERJ open research·2026

Related Experiment Video

Updated: Jul 4, 2025

Long Term Chronic Pseudomonas aeruginosa Airway Infection in Mice
15:43

Long Term Chronic Pseudomonas aeruginosa Airway Infection in Mice

Published on: March 17, 2014

22.8K

Accelerated Lung Function Decline and Mucus-Microbe Evolution in Chronic Obstructive Pulmonary Disease.

Oliver W Meldrum1, Gavin C Donaldson2, Jayanth Kumar Narayana1

  • 1Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore.

American Journal of Respiratory and Critical Care Medicine
|February 5, 2024
PubMed
Summary
This summary is machine-generated.

Accelerated lung function decline in chronic obstructive pulmonary disease (COPD) is linked to changes in mucus properties and the lung microbiome. These evolving mucus-microbiome interactions offer new therapeutic targets for early COPD intervention.

Keywords:
COPDlung function declinemetagenomicsmucusrheology

More Related Videos

Rapid Viscoelastic Characterization of Airway Mucus Using a Benchtop Rheometer
08:47

Rapid Viscoelastic Characterization of Airway Mucus Using a Benchtop Rheometer

Published on: April 21, 2022

3.3K
The WinCF Model - An Inexpensive and Tractable Microcosm of a Mucus Plugged Bronchiole to Study the Microbiology of Lung Infections
06:57

The WinCF Model - An Inexpensive and Tractable Microcosm of a Mucus Plugged Bronchiole to Study the Microbiology of Lung Infections

Published on: May 8, 2017

9.2K

Related Experiment Videos

Last Updated: Jul 4, 2025

Long Term Chronic Pseudomonas aeruginosa Airway Infection in Mice
15:43

Long Term Chronic Pseudomonas aeruginosa Airway Infection in Mice

Published on: March 17, 2014

22.8K
Rapid Viscoelastic Characterization of Airway Mucus Using a Benchtop Rheometer
08:47

Rapid Viscoelastic Characterization of Airway Mucus Using a Benchtop Rheometer

Published on: April 21, 2022

3.3K
The WinCF Model - An Inexpensive and Tractable Microcosm of a Mucus Plugged Bronchiole to Study the Microbiology of Lung Infections
06:57

The WinCF Model - An Inexpensive and Tractable Microcosm of a Mucus Plugged Bronchiole to Study the Microbiology of Lung Infections

Published on: May 8, 2017

9.2K

Area of Science:

  • Pulmonary Medicine
  • Microbiology
  • Biochemistry

Background:

  • Chronic obstructive pulmonary disease (COPD) is characterized by progressive lung function loss.
  • The relationship between accelerated lung function decline, mucus properties, and the lung microbiome in COPD remains understudied.

Purpose of the Study:

  • To longitudinally assess changes in mucus properties and the microbiome associated with accelerated lung function decline in COPD patients.
  • To identify specific mucus-microbiome signatures linked to disease progression.

Main Methods:

  • Prospective, longitudinal study of COPD patients with accelerated (n=30) and non-declining (n=28) FEV1.
  • Sputum samples analyzed using shotgun metagenomics for microbiome profiling.
  • Mucus biochemical and biophysical properties were evaluated.

Main Results:

  • Significant alterations in mucus biochemistry and biophysics were observed in the accelerated decline group.
  • A distinct mucus-microbiome association emerged in accelerated decline, with increased mucin (MUC5AC, MUC5B) and the presence of Achromobacter and Klebsiella.
  • As COPD progresses (GOLD A/B to E), mucus-microbiome shifts from low mucin/viscous to high mucin/elastic dominance with pathogenic bacteria.

Conclusions:

  • Mucus-microbiome associations dynamically evolve with accelerated lung function decline and symptom progression in COPD.
  • These findings highlight the interplay between mucus, microbes, and disease trajectory.
  • Understanding these evolving associations presents novel therapeutic opportunities for early intervention in COPD.